Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
Fig 8
Modulation of CD 133 expression by TMZ treatment.
A) Flow cytometry analysis of percentages of CD133 positives in tumor cell lines using TMZ treatment B: basal cells, 1C: first TMZ cycle; 2C: second TMZ cycle. Data were calculated from three independent experiments. B) Representative flow cytometry data for CD133 expression. SSC: side-scattered light.